OBJECTIVE: We evaluated whether reduced platelet activity detected by point-of-care (POC) testing is a better predictor of hematoma expansion and poor functional outcomes in patients with intracerebral hemorrhage (ICH) than a history of antiplatelet medication exposure. METHODS: Patients presenting with spontaneous ICH were enrolled in a prospective observational cohort study that collected demographic, clinical, laboratory, and radiographic data. We measured platelet activity using the PFA-100 (Siemens AG, Germany) and VerifyNow-ASA (Accumetrics, CA) systems on admission. We performed univariate and adjusted multivariate analyses to assess the strength of association between those measures and (1) hematoma growth at 24 hours and (2) functional outcomes measured by the modified Rankin Scale (mRS) at 3 months. RESULTS: We identified 278 patients for analysis (mean age 65 ± 15, median ICH score 1 [interquartile range 0-2]), among whom 164 underwent initial neuroimaging within 6 hours of symptom onset. Univariate association with hematoma growth was stronger for antiplatelet medication history than POC measures, which was confirmed in multivariable models (β 3.64 [95% confidence interval [CI] 1.02-6.26], P = .007), with a larger effect size measured in the under 6-hour subgroup (β 7.20 [95% CI 3.35-11.1], P < .001). Moreover, antiplatelet medication history, but not POC measures of platelet activity, was independently associated with poor outcome at 3 months (mRS 4-6) in the under 6-hour subgroup (adjusted OR 3.6 [95% CI 1.2-11], P = .023). CONCLUSION: A history of antiplatelet medication use better identifies patients at risk for hematoma growth and poor functional outcomes than POC measures of platelet activity after spontaneous ICH.
OBJECTIVE: We evaluated whether reduced platelet activity detected by point-of-care (POC) testing is a better predictor of hematoma expansion and poor functional outcomes in patients with intracerebral hemorrhage (ICH) than a history of antiplatelet medication exposure. METHODS:Patients presenting with spontaneous ICH were enrolled in a prospective observational cohort study that collected demographic, clinical, laboratory, and radiographic data. We measured platelet activity using the PFA-100 (Siemens AG, Germany) and VerifyNow-ASA (Accumetrics, CA) systems on admission. We performed univariate and adjusted multivariate analyses to assess the strength of association between those measures and (1) hematoma growth at 24 hours and (2) functional outcomes measured by the modified Rankin Scale (mRS) at 3 months. RESULTS: We identified 278 patients for analysis (mean age 65 ± 15, median ICH score 1 [interquartile range 0-2]), among whom 164 underwent initial neuroimaging within 6 hours of symptom onset. Univariate association with hematoma growth was stronger for antiplatelet medication history than POC measures, which was confirmed in multivariable models (β 3.64 [95% confidence interval [CI] 1.02-6.26], P = .007), with a larger effect size measured in the under 6-hour subgroup (β 7.20 [95% CI 3.35-11.1], P < .001). Moreover, antiplatelet medication history, but not POC measures of platelet activity, was independently associated with poor outcome at 3 months (mRS 4-6) in the under 6-hour subgroup (adjusted OR 3.6 [95% CI 1.2-11], P = .023). CONCLUSION: A history of antiplatelet medication use better identifies patients at risk for hematoma growth and poor functional outcomes than POC measures of platelet activity after spontaneous ICH.
Authors: Andrew M Naidech; Storm M Liebling; Neil F Rosenberg; Paul F Lindholm; Richard A Bernstein; H Hunt Batjer; Mark J Alberts; Hau C Kwaan Journal: Neurocrit Care Date: 2012-02 Impact factor: 3.210
Authors: Joseph P Broderick; Michael N Diringer; Michael D Hill; Nikolai C Brun; Stephan A Mayer; Thorsten Steiner; Brett E Skolnick; Stephen M Davis Journal: Stroke Date: 2007-02-08 Impact factor: 7.914
Authors: B B Thompson; Y Béjot; V Caso; J Castillo; H Christensen; M L Flaherty; C Foerch; K Ghandehari; M Giroud; S M Greenberg; H Hallevi; J C Hemphill; P Heuschmann; S Juvela; K Kimura; P K Myint; Y Nagakane; H Naritomi; S Passero; M R Rodríguez-Yáñez; J Roquer; J Rosand; N S Rost; P Saloheimo; V Salomaa; J Sivenius; T Sorimachi; M Togha; K Toyoda; W Turaj; K N Vemmos; C D A Wolfe; D Woo; E E Smith Journal: Neurology Date: 2010-09-08 Impact factor: 9.910
Authors: Andrew M Naidech; Sarice L Bassin; Richard A Bernstein; H Hunt Batjer; Mark J Alberts; Paul F Lindholm; Thomas P Bleck Journal: Neurocrit Care Date: 2009-12 Impact factor: 3.210
Authors: Matthew B Maas; Neil F Rosenberg; Adam R Kosteva; Rebecca M Bauer; James C Guth; Eric M Liotta; Shyam Prabhakaran; Andrew M Naidech Journal: Neurology Date: 2013-06-05 Impact factor: 9.910
Authors: Matthew B Maas; Alexander J Nemeth; Neil F Rosenberg; Adam R Kosteva; Shyam Prabhakaran; Andrew M Naidech Journal: Neurology Date: 2013-03-20 Impact factor: 9.910
Authors: Paul Harrison; Helen Segal; Kevin Blasbery; Charlene Furtado; Louise Silver; Peter M Rothwell Journal: Stroke Date: 2005-04-07 Impact factor: 7.914
Authors: Eric M Liotta; Shyam Prabhakaran; Rajbeer S Sangha; Robin A Bush; Alan E Long; Stephen A Trevick; Matthew B Potts; Babak S Jahromi; Minjee Kim; Edward M Manno; Farzaneh A Sorond; Andrew M Naidech; Matthew B Maas Journal: Neurology Date: 2017-07-26 Impact factor: 9.910